Stay updated with breaking news from Michael Krams. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
- Precision-designed potent and selective CDK7 inhibitor with potential for improved therapeutic index - - Preclinically discovered non-invasive PD biomarker to be confirmed alongside clinical trial -
- Study will enrol up to 110 patients in immunotherapy relapsed/refractory RCC and NSCLC - - Exscientia's A2A biomarker signature for patient selection will be prospectively tested during the trial
Exscientia plc (Nasdaq: EXAI) This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220525005906/en/ Recent advancements in the Company's pipeline
Exscientia plc This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220525005906/en/ Recent advancements in the Company’s pipeline,... | May 25, 2022
Exscientia plc (Nasdaq: EXAI) today announced the appointment of Michael Krams, M.D., as its Chief Quantitative Medicine Officer. In this newly created role, Dr. Krams will lead clinical development